Karachi: Abbott Laboratories (Pakistan) Limited's Board of Directors convened on Tuesday, October 27th, 2026, to approve the financial results for the nine months and quarter ending September 30th, 2026. The meeting, held at the company's City Office in Karachi, revealed notable financial growth compared to the previous year.
For the nine months ending September 30, 2026, the company's net sales increased to 58.66 billion rupees from 58.23 billion rupees in the same period in 2025. This period saw local sales rise to 57.14 billion rupees from 53.91 billion rupees, while export sales decreased to 1.52 billion rupees from 2.32 billion rupees.
The cost of sales for the nine-month period decreased to 36.44 billion rupees from 36.89 billion rupees. Consequently, gross profit experienced an increase, reaching 22.21 billion rupees, compared to 19.34 billion rupees in the previous year. The company's selling and distribution expenses rose to 9.04 billion rupees from 8.50 billion rupees, and administrative expenses increased to 1.10 billion rupees from 972.48 million rupees. Other charges also saw an increase, amounting to 1.36 billion rupees from 1.26 billion rupees.
Despite these rising expenses, Abbott Laboratories (Pakistan) Limited reported a profit before taxation of 11.40 billion rupees, up from 9.16 billion rupees. The net profit for the period rose significantly to 6.68 billion rupees from 5.37 billion rupees in the same period of the previous year. According to information available from the Pakistan Stock Exchange (PSX), this reflects a very large or significant move in profitability.
For the quarter ending September 30, 2026, the company posted net sales of 20.63 billion rupees, compared to 19.82 billion rupees in the same quarter of 2025. The cost of sales decreased to 12.87 billion rupees from 13.09 billion rupees, resulting in a gross profit of 7.76 billion rupees compared to 6.73 billion rupees previously. The quarter's profit before taxation was 4.20 billion rupees, a notable increase from 3.16 billion rupees in the corresponding quarter of the previous year. The net profit for this quarter stood at 2.54 billion rupees, compared to 1.82 billion rupees in 2025.
The basic and diluted earnings per share for the nine-month period increased to 68.28 rupees from 54.81 rupees, while for the quarter, it rose to 25.99 rupees from 18.62 rupees.
Abbott Laboratories (Pakistan) Limited operates within the designated market category of the pharmaceutical industry.